Skip to main content

Advertisement

SpringerLink
Log in

Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report

  • Case Report
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

The CLEOPATRA trial reported the survival benefit of pertuzumab with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients. However, there are a few case reports concerning the effects of a pertuzumab-containing regimen on brain metastases. A 55-year-old woman, who underwent curative surgery for breast cancer after neoadjuvant chemotherapy 5 years previously, developed repeated solitary brain metastasis in her right occipital lobe. Whole brain radiation therapy, stereotactic radiosurgery and 3 times of surgical resection were performed. Lapatinib and capecitabine plus tamoxifen were administered. The metastasis recurred in the stump of the previous surgery. Pertuzumab with trastuzumab plus docetaxel was initiated as second-line chemotherapy. A complete response of the brain metastasis was achieved, which persisted for 5 months. Pertuzumab with trastuzumab plus docetaxel was effective in reducing the brain metastases from breast cancer. Further studies are warranted to confirm the effect of this regimen on brain metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya R. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–72.

    Article  PubMed  Google Scholar 

  2. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma autopsy study. Cancer. 1983;52:2349–54.

    Article  CAS  PubMed  Google Scholar 

  3. Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat. 2012;136:153–60.

    Article  PubMed  Google Scholar 

  4. Yerushalmi R, Woods R, Kennecke H, Speers C, Knowling M, Gelmon K. Patterns of relapse in breast cancer: changes over time. Breast Cancer Res Treat. 2010;120:753–9.

    Article  CAS  PubMed  Google Scholar 

  5. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13:1648–55.

    Article  CAS  PubMed  Google Scholar 

  6. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17:4834–43.

    Article  CAS  PubMed  Google Scholar 

  7. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271–7.

    Article  PubMed  Google Scholar 

  8. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer. 2012;118:4652–9.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113:2638–45.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.

    Article  CAS  PubMed  Google Scholar 

  11. Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14:244–8.

    Article  CAS  PubMed  Google Scholar 

  12. Langkjer ST, Kroldrup L, Kristiansen C, Enevoldsen K, Edal AL, Ormstrup TE. High incidence of brain metastases found in patients with HER2-positive metastatic breast cancer: should these patients be followed with regular MR scans? Breast Cancer Res Treat. 2001;106:S53.

    Google Scholar 

  13. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer. 2004;101:810–6.

    Article  CAS  PubMed  Google Scholar 

  14. Lower EE, Drosick DR, Blau R, Brennan L, Dannerman W, Hawley DK. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer. 2003;4:114–9.

    Article  CAS  PubMed  Google Scholar 

  15. Pinder MC, Chang H, Broglio KR, Michaud LB, Theriault RL, Sahin A, et al. Trastuzumab treatment and the risk of central nervous system (CNS) metastases. J Clin Oncol. 2007;25:18S.

    Article  Google Scholar 

  16. Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer. 2009;100:894–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Larsen PB, Kümler I, Nielsen DL. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. Cancer Treat Rev. 2013;39:720–7.

    Article  CAS  PubMed  Google Scholar 

  18. Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol. 2011;22:625–30.

    Article  CAS  PubMed  Google Scholar 

  19. Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases—the UK experience. Br J Cancer. 2010;102:995–1002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14:64–71.

    Article  CAS  PubMed  Google Scholar 

  21. Pivot X, Semiglazov V, Zurawski BE. CEREBEL (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2 metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) versus trastuzumab plus capecitabine (TC). ESMO 2012 Annual Meeting LBA11; 2012.

  22. Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, et al. Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. Breast Cancer Res Treat. 2015;149:277–84.

    Article  CAS  PubMed  Google Scholar 

  23. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anticancer Drugs. 2007;18:23–8.

    Article  CAS  PubMed  Google Scholar 

  24. Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, et al. HER2 dimerization inhibitor pertuzumab—mode of action and clinical data in breast cancer. Breast Care. 2013;8:49–55.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol. 2010; 21(supplement 7):vii36–40.

  26. Mehta AI, Brufsky AM, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood–brain barrier. Cancer Treat Rev. 2013;39:261–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lewis KM, Harford-Wright E, Vink R, Nimmo AJ, Ghabriel MN. Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion. Clin Exp Metastasis. 2013;30:1–12.

    Article  CAS  PubMed  Google Scholar 

  28. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28:803–14.

    Article  CAS  PubMed  Google Scholar 

  29. Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25:1116–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank Dr. Akira Yamauchi of Kitano Hospital (Osaka, Japan) for critically reviewing the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Breast Surgery, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka, Osaka, 543-8555, Japan

    Noriko Senda, Ayane Yamaguchi & Shigeru Tsuyuki

  2. Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Ayane Yamaguchi

  3. Department of Brain Surgery, Osaka Red Cross Hospital, Osaka, Japan

    Hideaki Nishimura

  4. Department of Diagnostic Radiology, Osaka Red Cross Hospital, Osaka, Japan

    Toshiki Shiozaki

Authors
  1. Noriko Senda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayane Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideaki Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshiki Shiozaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shigeru Tsuyuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noriko Senda.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Senda, N., Yamaguchi, A., Nishimura, H. et al. Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report. Breast Cancer 23, 323–328 (2016). https://doi.org/10.1007/s12282-015-0623-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-015-0623-x

Keywords

Search

Navigation